Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr Tan on the Implications of Data From an Analysis of the PDIGREE Trial for Dual Checkpoint Blockade in ccRCC

July 2nd 2025

Alan Tan, MD, discusses the clinical significance and next steps for evaluating the relative safety of IO vs IO/TKI regimens in ccRCC.

Low KIM-1 Levels Are Associated With Improved Clinical Outcomes in Advanced RCC

July 2nd 2025

A research fellow from Dana-Farber Cancer Institute shares post hoc findings from the phase 3 JAVELIN Renal 101 trial.

2025 Giants of Cancer Care: OncLive® Honors 13 Cancer Care Pioneers

June 30th 2025

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.

Tivozanib Monotherapy May Serve as Effective Second-Line Option in Metastatic RCC

June 27th 2025

Alexander Chehrazi-Raffle, MD, discusses the efficacy of tivozanib monotherapy after receipt of upfront IO/TKI or ipilimumab/nivolumab in RCC.

ALLO-316 Produces Responses in Heavily Pretreated Clear Cell Renal Carcinoma

June 26th 2025

ALLO-316 showed activity and a tolerable safety profile in patients with pretreated advanced or metastatic clear cell renal cell carcinoma.

5-Year Analysis of KEYNOTE-564 Reinforces Role of Adjuvant Pembrolizumab as SOC in ccRCC

June 24th 2025

Naomi B. Haas, MD, delves into the KEYNOTE-564 trial and highlights the role of adjuvant pembrolizumab in clear cell renal cell carcinoma.

Dr Pal on Genomic Activity With Adjuvant Atezolizumab vs Placebo in High-Risk Resected RCC

June 23rd 2025

Sumanta Kumar Pal, MD, FASCO, discusses the genomic activity of adjuvant atezolizumab vs placebo in patients with high-risk resected RCC.

Dr Tan on Important Considerations for Nivolumab/Ipilimumab Selection in Metastatic ccRCC

June 17th 2025

Alan Tan, MD, emphasizes the importance of considering safety profiles and patient-related factors before selecting an IO regimen in metastatic ccRCC.

Dr Chehrazi-Raffle on the Safety of Second-Line Tivozanib With/Without Nivolumab in RCC

June 13th 2025

Alexander Chehrazi-Raffle, MD, details safety data and the clinical implications of an analysis of second-line tivozanib for patients with metastatic RCC.

Dr Haas on 5-Year Outcomes With Adjuvant Pembrolizumab in ccRCC

June 5th 2025

Naomi B. Haas, MD, shares 5-year follow-up data with adjuvant pembrolizumab in patients with clear cell renal cell carcinoma.

China’s NMPA Accepts NDA for Sintilimab Plus Fruquintinib in Second-Line Advanced/Metastatic RCC

June 5th 2025

A new drug application seeking the Chinese approval of sintilimab plus fruquintinib in second-line advanced/metastatic RCC has been accepted by the NMPA

Machine Learning–Based Approach Improves Outcome Prediction vs Individual Biomarkers in RCC

June 5th 2025

The evaluation of diverse biomarkers via a machine learning approach demonstrated improved prediction of clinical outcomes vs individual biomarkers in RCC.

Single-Agent Tivozanib Shows Activity in Metastatic RCC After Contemporary Frontline Therapy

June 4th 2025

Tivozanib monotherapy was effective and outperformed tivozanib plus nivolumab after receipt of upfront IO/TKI or ipilimumab/nivolumab regimens in RCC.

Cabozantinib Displays Activity as Combination Component and Monotherapy in Second-Line Advanced RCC

June 2nd 2025

Cabozantinib plus atezolizumab or cabozantinib alone was effective regardless of prior immunotherapy or TKI treatment in second-line advanced RCC.

Long-Term Data Demonstrate Sustained DFS Benefit With Adjuvant Pembrolizumab in ccRCC

June 1st 2025

Adjuvant pembrolizumab showed maintained OS and DFS vs placebo in patients with ccRCC at the 5-year analysis.

Nivolumab/Ipilimumab Maintains Prolonged Survival and Generates Durable Responses in Advanced RCC

June 1st 2025

First-line nivolumab/ipilimumab demonstrated sustained survival signals and responses vs sunitinib in previously untreated advanced RCC.

Dr Matrana on the Persisting Need For Validated Biomarkers to Guide Treatment Selection in RCC

May 31st 2025

Marc R. Matrana, MD, discusses the ongoing need for validated biomarkers to guide treatment selection in renal cell carcinoma.

Dr Matrana on Advantages and Challenges of the Expanding First-Line RCC Treatment Paradigm

May 30th 2025

Marc Matrana, MD, discusses how the expansion of the frontline RCC treatment paradigm opens the door to further questions regarding personalized treatment.

Dr Vento on the Role of IO/TKI Combos in Non–Clear Cell RCC

May 29th 2025

Joseph Vento, MD, highlights the role of IO/TKI combinations for the treatment of patients with non–clear cell renal cell carcinoma.

Health Canada, European Commission Approve Subcutaneous Nivolumab in the Same Solid Tumor Indications as IV Formulation

May 28th 2025

Nivolumab has been approved for subcutaneous use across several adult solid tumor indications that have an existing indication for intravenous use.